Erlotinib HCl (OSI-744)

For research use only. Not for use in humans.

目录号：S1023 别名： CP358774, NSC 718781 中文名称：盐酸厄洛替尼

Erlotinib HCl (OSI-744) Chemical Structure

CAS No. 183319-69-9

Erlotinib HCl (OSI-744, CP358774, NSC 718781)是一种EGFR抑制剂，在无细胞试验中IC50为2 nM，对EGFR的选择性比对人c-Src或v-Abl高1000多倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1564.29	现货
100mg	RMB 1183.19	现货
300mg	RMB 2211.3	现货
500mg	RMB 3012.92	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Erlotinib HCl (OSI-744)发表文献410篇：

Cell, 2019, 178(4):807-819.e21

PubMed: 31398338 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Cell Metab, 2019, 30(3):525-538

PubMed: 31303424 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(1):91-106

PubMed: 28457749 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2013, 3(12):1404-15

PubMed: 24065731 ( click the link to review the publication )

Cell Metab, 2013, 17(6):1000-8

PubMed: 23707073 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Genet, 2012, 44(8):852-60

PubMed: 22751098 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Exp Ther Med, 2021, 21(1):9

PubMed: 33235618 ( click the link to review the publication )

Oncol Lett, 2021, 21(1):44

PubMed: 33262836 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1792

PubMed: 32286289 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )
Cell Rep, 2020, 31(13):107840

PubMed: 32610141 ( click the link to review the publication )

Mucosal Immunol, 2020, 4

PubMed: 32132671 ( click the link to review the publication )

Oncogene, 2020, 39(15):3163-3178

PubMed: 32051553 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(1) pii: E173

PubMed: 31936715 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):66

PubMed: 32552913 ( click the link to review the publication )

Cells, 2020, 17;9(4) pii: E1003

PubMed: 32316635 ( click the link to review the publication )

Cancer Discov, 2020, CD-19-1262

PubMed: 32513774 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19;molcanther10362019

PubMed: 32430488 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371586 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 11(19):5746-5757

PubMed: 32913468 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30257-7

PubMed: 33197651 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Eur J Pharm Biopharm, 2020, S0939-6411(20)30305-2

PubMed: 33068736 ( click the link to review the publication )
Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0420

PubMed: 33028660 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:585292

PubMed: 33194732 ( click the link to review the publication )

Front Oncol, 2020, 10:1593

PubMed: 33014812 ( click the link to review the publication )

J Cell Sci, 2020, jcs.238840

PubMed: 32546532 ( click the link to review the publication )

J Cell Mol Med, 2020, 22

PubMed: 32441057 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(2)

PubMed: 31940844 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9307

PubMed: 33291316 ( click the link to review the publication )

Sci Rep, 2020, 13;10(1):4722

PubMed: 32170113 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):959

PubMed: 31969600 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.014960

PubMed: 33273014 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxins (Basel), 2020, 12(12)E753

PubMed: 33260619 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4453-4460

PubMed: 32606939 ( click the link to review the publication )

Mol Med, 2020, 26(1):66

PubMed: 32611363 ( click the link to review the publication )

BMC Cancer, 2020, 4;20(1):375

PubMed: 32366230 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227261

PubMed: 31914141 ( click the link to review the publication )
Onco Targets Ther, 2020, 13:10983-10994

PubMed: 33149613 ( click the link to review the publication )

Thorac Cancer, 2020, 11

PubMed: 32525282 ( click the link to review the publication )

Chin Med, 2020, 15:66

PubMed: 32612672 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Am Soc Nephrol, 2020, ASN.2019111215

PubMed: 32616537 ( click the link to review the publication )

Cancer Metab, 2020, 8:19

PubMed: 32974013 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Oncotarget, 2020, 11(46):4224-4242

PubMed: 33245718 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2020, 106895

PubMed: 32629158 ( click the link to review the publication )

Pharmaceutics, 2020, 12(2)

PubMed: 32028611 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Small, 2019, 15(33):e1900309

PubMed: 31245925 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2220-2231

PubMed: 30890618 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3341-3351

PubMed: 30796031 ( click the link to review the publication )

Clin Cancer Res, 2019, 1;25(19):5866-5877

PubMed: 31431454 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )
Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):211

PubMed: 31118055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Anal Chem, 2019, 91(15):10026-10032

PubMed: 31282657 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):282

PubMed: 30910997 ( click the link to review the publication )

Br J Cancer, 2019, 120(3):306-316

PubMed: 30585254 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1565-1576

PubMed: 31270152 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Oncogenesis, 2019, 8(12):70

PubMed: 31772161 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(4):1002-1012

PubMed: 30635434 ( click the link to review the publication )

Front Oncol, 2019, 9:461

PubMed: 31214503 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Sci Rep, 2019, 9(1):845

PubMed: 30696915 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2357

PubMed: 30787334 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Biol Chem, 2019, 294(27):10530-10543

PubMed: 31126985 ( click the link to review the publication )

J Biol Chem, 2019, 294(21):8336-8347

PubMed: 30979723 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:4254759

PubMed: 30863451 ( click the link to review the publication )
Respir Res, 2019, 20(1):270

PubMed: 31791326 ( click the link to review the publication )

Mol Imaging Biol, 2019, 21(4):696-704

PubMed: 30377939 ( click the link to review the publication )

J Ethnopharmacol, 2019, 239:111928

PubMed: 31077779 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Dev Biol, 2019, 10.1016/j.ydbio.2019.10.006

PubMed: 31610144 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2719-2729

PubMed: 31911857 ( click the link to review the publication )

Spectrochim Acta A Mol Biomol Spectrosc, 2019, 10.1016/j.saa.2019.117737

PubMed: 31757706 ( click the link to review the publication )

JCI Insight, 2019, 10.1172/jci.insight.127552

PubMed: 31237864 ( click the link to review the publication )

Immunity, 2018, 49(1):134-150

PubMed: 29958800 ( click the link to review the publication )

J Exp Med, 2018, 215(1):115-140

PubMed: 29191914 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

PLoS Biol, 2018, 16(9):e2006624

PubMed: 30261040 ( click the link to review the publication )

PLoS Biol, 2018, 16(12):e2006660

PubMed: 30543635 ( click the link to review the publication )

Cell Syst, 2018, 6(3):343-354

PubMed: 29428415 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4344-4359

PubMed: 29844121 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Mol Cancer, 2018, 17(1):50

PubMed: 29455661 ( click the link to review the publication )

Int J Cancer, 2018, 143(8):1994-2007

PubMed: 29756386 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):156-164

PubMed: 28906000 ( click the link to review the publication )

Cancer Lett, 2018, 436:1-9

PubMed: 30118839 ( click the link to review the publication )

Cancer Lett, 2018, 434:152-159

PubMed: 30036610 ( click the link to review the publication )
Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

J Pathol, 2018, 244(2):242-253

PubMed: 29160922 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):31

PubMed: 29458405 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):684

PubMed: 29880898 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):219

PubMed: 29440633 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 11:455-467

PubMed: 29858080 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 12:817-828

PubMed: 30153566 ( click the link to review the publication )

Stem Cells, 2018, 36(8):1273-1285

PubMed: 29726088 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(3):957-971

PubMed: 29843133 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11):2297-2308

PubMed: 30093568 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):732-739

PubMed: 29467274 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

MAbs, 2018, 10(7):1003-1017

PubMed: 30130447 ( click the link to review the publication )

Cell Biol Toxicol, 2018, 34(6):459-469

PubMed: 29478126 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):2063-2073

PubMed: 29701925 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2391-2400

PubMed: 29927028 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(12):2419-2435

PubMed: 30662801 ( click the link to review the publication )
Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Lung Cancer, 2018, 122:44-53

PubMed: 30032844 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):6975-6983

PubMed: 29336487 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386292 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(6):3073-3085

PubMed: 29575527 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 29933569 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3317

PubMed: 29463831 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Gene, 2018, 642:95-102

PubMed: 29133145 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 59(6):695-705

PubMed: 30011381 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:565-581

PubMed: 29606890 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:887-897

PubMed: 29740218 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30226590 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):527-538

PubMed: 29845246 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):249

PubMed: 29506489 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):191

PubMed: 29448920 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )
Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(5):829-838

PubMed: 30167846 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:5499-5508

PubMed: 30233210 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:3087-3100

PubMed: 29872320 ( click the link to review the publication )

Curr Cancer Drug Targets, 2018, 18(3):278-286

PubMed: 28359236 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1292-1299

PubMed: 29885023 ( click the link to review the publication )

Mol Med Rep, 2018, 17(2):2509-2514

PubMed: 29207200 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):935-943

PubMed: 30074936 ( click the link to review the publication )

Acta Haematol, 2018, 140(1):30-39

PubMed: 30071517 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Biologics, 2018, 12:75-86

PubMed: 30154647 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12020-12034

PubMed: 29552290 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018, 9(79):34996-35007

PubMed: 30405889 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29568372 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(5):518-529

PubMed: 28414315 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )
Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Nat Commun, 2017, 8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1420

PubMed: 29127277 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Autophagy, 2017, 13(3):579-591

PubMed: 28103122 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3769-3780

PubMed: 28174235 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(2):579-589

PubMed: 27671677 ( click the link to review the publication )

J Control Release, 2017, 262:58-71

PubMed: 28694030 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.27388

PubMed: 28980940 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.33173

PubMed: 29087937 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.20444

PubMed: 28195529 ( click the link to review the publication )

Oncogene, 2017, 36(48):6747-6748

PubMed: 29188822 ( click the link to review the publication )

Oncogene, 2017, 36(47):6542-6554

PubMed: 28759046 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2980

PubMed: 28796259 ( click the link to review the publication )
Cell Death Dis, 2017, 8(9):e3033

PubMed: 28880262 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Oncol, 2017, 11(8):1065-1077

PubMed: 28486761 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):670-681

PubMed: 28388009 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):628-639

PubMed: 28306189 ( click the link to review the publication )

Radiother Oncol, 2017, 124(3):504-512

PubMed: 28823407 ( click the link to review the publication )

Cancer Sci, 2017, 108(1):53-60

PubMed: 27783866 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29156644 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16763

PubMed: 29196706 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(10)

PubMed: 28265001 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

Phytomedicine, 2017, 36:59-67

PubMed: 29157829 ( click the link to review the publication )

Int J Oncol, 2017, 50(6):2049-2058

PubMed: 28440469 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )
BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):915-926

PubMed: 28052650 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Biosci Rep, 2017, 37(3)

PubMed: 28507201 ( click the link to review the publication )

Environ Toxicol, 2017, 32(5):1628-1636

PubMed: 28101945 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189087

PubMed: 29253018 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Clin Exp Nephrol, 2017, 10.1007/s10157-017-1386-9

PubMed: 28176019 ( click the link to review the publication )

Oncol Lett, 2017, 14(3):3445-3454

PubMed: 28927099 ( click the link to review the publication )

J Vis Exp, 2017, 126

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1:PO.16.00019

PubMed: 32913967 ( click the link to review the publication )

Gels, 2017, 3(3)

PubMed: 30920523 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109068-109078

PubMed: 29312591 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98771-98781

PubMed: 29228726 ( click the link to review the publication )

Cancer Metab, 2017, 5:6

PubMed: 28852500 ( click the link to review the publication )

Oncotarget, 2017, 8(13):20961-20973

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )
Oncotarget, 2017, 8(38):63014-63025

PubMed: 28968967 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111333-111345

PubMed: 29340057 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73745-73756

PubMed: 29088741 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109068-109078

PubMed: 29312591 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

PLoS Pathog, 2016,

PubMed: 27711202 ( click the link to review the publication )

Cell Death Dis, 2016,

PubMed: 27685624 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Sci Rep, 2016, 6:32809

PubMed: 27609096 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 48(5):1855-67

PubMed: 26936292 ( click the link to review the publication )

J Drug Target, 2016, 25(2):125-131

PubMed: 27633093 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )
Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 8(52):89552-89565

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26551-66

PubMed: 27034169 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015,

PubMed: 26195767 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2005

PubMed: 25744720 ( click the link to review the publication )

Cancer Prev Res (Phila), 2015, 8(9):765-76

PubMed: 26100522 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29483

PubMed: 25688715 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25659577 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.03.014

PubMed: 25779676 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26538233 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

J Biol Chem, 2015,

PubMed: 26152725 ( click the link to review the publication )

BMC Genomics, 2015, 16 Suppl 12:S2

PubMed: 26681397 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2751-6

PubMed: 25907508 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140782

PubMed: 26474061 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )
J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Anal Biochem, 2015, 10.1016/j.ab.2015.01.016

PubMed: 25659657 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9206-19

PubMed: 25826078 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14329-43

PubMed: 25869210 ( click the link to review the publication )

Oncotarget, 2015, 9(38):24914-24926

PubMed: 29861842 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26486084 ( click the link to review the publication )

J Hepatol, 2014, 60(1):143-51

PubMed: 23978713 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(15):4047-58

PubMed: 24895459 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )
Antioxid Redox Sign, 2014, 10.1089/ars.2013.5304

PubMed: 24684506 ( click the link to review the publication )

Sci Signal, 2014, 7(338):ra75

PubMed: 25118327 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(9):2203-14

PubMed: 25028470 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):152-60

PubMed: 24954871 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

J Transl Med, 2014, 12(1):265

PubMed: 25240937 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):649-663

PubMed: ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 351(2):352-8

PubMed: 25187431 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

Oncol Res, 2014, 21(3):137-44

PubMed: 24512728 ( click the link to review the publication )

BMC Microbiol, 2014,

PubMed: 25471819 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Histochem Cell Biol, 2014, 10.1007/s00418-014-1223-0

PubMed: 24824474 ( click the link to review the publication )

Biores Open Access, 2014, 3(4):176-82

PubMed: 25126481 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(24):6842-52

PubMed: 24130071 ( click the link to review the publication )

Cell Rep, 2013, 4(4):764-75

PubMed: 23972990 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

BRIT J CANCER, 2013, 109(8):2155-66

PubMed: 24045666 ( click the link to review the publication )

Lung Cancer, 2013, 81(3):354-61

PubMed: 23769318 ( click the link to review the publication )
Invest Ophthalmol Vis Sci, 2013, 54(1):864-70

PubMed: 23299479 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62104

PubMed: 23690929 ( click the link to review the publication )

Laser in Surg Med, 2013, 45(7):460-8

PubMed: 24037824 ( click the link to review the publication )

Head Neck, 2013, 35(1):86-93

PubMed: 22495823 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23896512 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

J Clin Invest, 2012, 122(9):3197-210

PubMed: 22886302 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Cancer, 2012, 118(21):5198-209

PubMed: 22510844 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(10):e48532

PubMed: 23119048 ( click the link to review the publication )

Oncogene, 2011, 30(22):2547-57

PubMed: 21278786 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Microvasc Res, 2011, 81(1):135-42

PubMed: 21067705 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(4):577-86

PubMed: 20097731 ( click the link to review the publication )
Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Case Western Reserve University, 2010, Zhang Z

PubMed: ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

Erlotinib HCl (OSI-744, CP358774, NSC 718781)是一种EGFR抑制剂，在无细胞试验中IC50为2 nM，对EGFR的选择性比对人c-Src或v-Abl高1000多倍。

靶点

HER1/EGFR ^[1]
(Cell-free assay)

2 nM

体外研究

Erlotinib作用于HNS人头部和颈部肿瘤细胞，有效抑制EGFR自磷酸化，HNS人头部和颈部肿瘤细胞是表达高水平EGFR的细胞系。^[1] Erlotinib对SBC-5细胞增殖没有作用效果。相反, Erlotinib 显著抑制PC-9细胞增殖,这种作用存在剂量依赖性，PC-9细胞在EGFR基因第19外显子含缺失突变。Erlotinib处理也不会影响SBC-5细胞迁移。^[2] Erlotinib 抑制HPAC细胞和Capan-1细胞生长， IC50 分别为1.1和3µM。10 uM Erlotinib 抑制EGFR在 Y845 (Src依赖性磷酸化) 和和Y1068(自磷酸化)位点磷酸化。^[3] Erlotinib 只有作用于最敏感的细胞株时，抑制细胞外信号调节激酶, Akt, 和S6。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human SKBR3 cells	NXLVN2g4TnWwY4Tpc44h[XO\|YYm=			NYnvVJJTUW6qaXLpeIlwdiCxZjDISXIzKGmwIHj1cYFvKFONQmKzJINmdGy\|IHL5JGhVWkZiYYPzZZktKEmFNUC9NU45QSEQvF2u	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQThzNUSxNkc,OTl6MUW0NVI9N2F-
human A431 cells	NYe3SWk{TnWwY4Tpc44h[XO\|YYm=			NELIeW9KdmirYnn0bY9vKG:oIFXHSnIhcW5iaIXtZY4hSTR\|MTDj[YxteyCkeTDIWHJHKGG\|c3H5MEBKSzVyPUCuOFIh\|ryPLh?=	NXTDcpFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVU1OTJpPkG5PFE2PDF{PD;hQi=>
A431	MnzBSpVv[3Srb36gZZN{[Xl?			MnfJTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMh[nlicHjvd5Bpd3S7cn;zbY5mKEWOSWPBJIF{e2G7LDDJR\|UxKD1iMD6wNFEzKM7:TT6=	M4TFRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEmwOlUzLz5{NEi5NFY2OjxxYU6=
MCF7	NHvuOHpEgXSxdH;4bYNqfHliYYPzZZk>			M4nyU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNuIFnDOVAhRSByLkCwNVIh\|ryPLh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh7ME[1Nkc,OjR6OUC2OVI9N2F-
A431	MVXGeY5kfGmxbjDhd5NigQ>?		MWO2NEBucW6\|	NXfJWIY{UW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIHHjeIl3[XSrb36gbY4hcHWvYX6gRVQ{OSClZXzsd{BxemW2cnXheIVlKG[xcjC2NEBucW6\|IH\vcIxwf2WmIHL5JGVITiCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxNkDPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
A431	NHH6cVVHfW6ldHnvckBie3OjeR?=		MmnQOlAhdWmwcx?=	M1zFW2lvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGT0ZiaX7keYNm\CCyaH;zdIhwenmuYYTpc44heHKnaX7jeYJifGWmIH\vdkA3OCCvaX7zJIZwdGyxd3XkJIJ6KEWJRjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IFXMTXNCKG2ndHjv[EwhUUN3MDC9JFAvODBzMjFOwG0v	M4nqeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEm0OVg6Lz5{N{i5OFU5QTxxYU6=
A431	NGnxZ2FHfW6ldHnvckBie3OjeR?=		NUfvO4xVPjBibXnudy=>	MkDITY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMh[2:vcH;1coQheHKndILlZZRm\CCob4KgOlAhdWmwIHLl[o9z\SCHR1[gd5RqdXWuYYTpc44h\m:{IEGwJI1qdnNiYomgdIhwe3Cqb4T5do9{cW6nIFXMTXNCKGO7dH;icI91KG2ndHjv[EwhUUN3MDC9JFAvODBzMjFOwG0v	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6MkWxPUc,OjV6OEK1NVk9N2F-
HCC827	NX;sbpNtS3m2b4TvfIlkcXS7IHHzd4F6		M1P1WFQ5KGi{cx?=	MmnCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEQDJ5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByMjFOwG0v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
PC9	NV;6U3g3TnWwY4Tpc44h[XO\|YYm=		NH;pdo8zKGi{cx?=	NEnN[WtKdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVGM6KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFA2QSEQvF2u	NFTsW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzNFk6PCd-MkO5N\|A6QTR:L3G+
NCI-H292	M2DibmZ2dmO2aX;uJIF{e2G7		NXzy[m1nOSCqch?=	NVrnfpdRUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBPS0lvSEK5NkBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlic4TpcZVt[XSrb36ge4l1cCCHR1[g[o9zKDhibXnud{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XueEBqdW23bn;hd5NigSxiSVO1NEA:KDBwMEC2N{DPxE1w	NWK1VFNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OVU6OTlpPkK2OFU2QTF7PD;hQi=>
HCC827	M{\LPGZ2dmO2aX;uJIF{e2G7		Mn3TNkBpenN?	MYPJcohq[mm2aX;uJI9nKEWJRmKg[IVt\XSrb36gcZV1[W62IHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTGNEQDJ5IHPlcIx{KGGodHXyJFIhcHK\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNFgh\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
MCF7	NUHIfWVPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MV:0PEBpenN?	M3noO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNUDPxE1w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
H3255	MWTGeY5kfGmxbjDhd5NigQ>?		MUOyJIhzew>?	MnThTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFizNlU2KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hOC5yMTFOwG0v	MnPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H3255	MnnTSpVv[3Srb36gZZN{[Xl?		M1PJflIhcHK\|	M1XqS2lvcGmkaYTpc44hd2ZiRVfGVkBNQDV6UjDteZRidnRicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEh\|MkW1JINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliRVfGJJN1cW23bHH0bY9vKG[xcjCxNEBucW6\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNUDPxE1w	NYfhcWptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
PC9	NWjSVHpzTnWwY4Tpc44h[XO\|YYm=		MXeyJIhzew>?	MknXTY5pcWKrdHnvckBw\iCHR1\SJIRmdGW2aX;uJI12fGGwdDDheZRweGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGxJO69VS5?	NX;EdVJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
A549	M1vZ[WZ2dmO2aX;uJIF{e2G7		M4\5flIhcHK\|	NFLpbG9KdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKHerbHSteJlx\SCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDBOVQ6KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyOCCvaX7zJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gNE4xOTFizszNMi=>	M{PRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
PC9	MlPISpVv[3Srb36gZZN{[Xl?		NUPsR25LOiCqcoO=	MXTJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFCFOTDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUCgcYlveyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGxJO69VS5?	NWHDXHBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
A549	M{DKR2Z2dmO2aX;uJIF{e2G7			NUf4[Xl6UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CC5aXzkJJR6eGViRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCDNUS5JINmdGy\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
BA/F3	NG\DSmlEgXSxdH;4bYNqfHliYYPzZZk>			MmH6R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCxiSVO1NEA:KDBwMEGyOUDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ\|OUKyPUc,OTl{M{myNlk9N2F-
KB	NEHreZlHfW6ldHnvckBie3OjeR?=		MYGxJIhz	M1q5fmlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEuEIHPlcIx{KGmwY4XiZZRm\CCob4KgNUBpeiCycnnvdkB1dyCHR1[gZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IE[gcYlveyCkeTDFUGlUSSxiSVO1NEA:KDBwMEG5JO69VS5?	M2q4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
NIH3T3	MWPGeY5kfGmxbjDhd5NigQ>?			M1TRXGlvcGmkaYTpc44hd2ZiRVfGJJN1cW23bHH0[YQhcHWvYX6g[ZJjSjFiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBPUUh\|VEOgZ4VtdHNuIFnDOVAhRSByLkCxPVMh\|ryPLh?=	NVnjU5lzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0PFAzQDRpPkG2OFgxOjh2PD;hQi=>
MCF7	MnTERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn63OFghcHK\|	MoHVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|UoRjF7OUG0PFM2RC:jPh?=
Sf9	M2HITWZ2dmO2aX;uJIF{e2G7			MVzJcohq[mm2aX;uJI9nKGOub37l[EBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBk\WyuczDifUB{d2yrZD3wbIF{\SCHTFnTRUwhUUN3MDC9JFAvODJizszNMi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
MCF7	NEXqSWJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGi3e2Q1QCCqcoO=	NGHVZoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFIh\|ryPLh?=	NFjTZWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MECwOVEyPid-MkCwNFUyOTZ:L3G+
MCF7	NUPJ[I5wSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NH;5dGQ1QCCqcoO=	NW[wVmxnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NGP0eGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW5OFg2QSd-MkC1PVQ5PTl:L3G+
MCF7	M3fpTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVTMXoNnPDhiaILz	NUGzSVM5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NYPoXnBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|c2QDhpPkKyNlc4PTh6PD;hQi=>
A16-F10	MmfYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXPXd29yPDhiaILz	MluzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDMU[tSlExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NGDYWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
MCF7	NUCx[XlyS3m2b4TvfIlkcXS7IHHzd4F6		NXvzSm8zPDhiaILz	Mk\sR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	M2XYTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOECyNlkxLz5{MUiwNlI6ODxxYU6=
MCF7	M{H2dmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3zDeFQ5KGi{cx?=	M{jRN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODJizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{N{W5O{c,OjB4Mke1PVc9N2F-
HT-29	Mn\xRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFjWcFU1QCCqcoO=	NWrtc49ZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	NVfY[5VoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
MCF7	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmTZOFghcHK\|	NV31WWZ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NWPPbGdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU5ODJpPkKzNlQ2QDB{PD;hQi=>
HCC827	MlSzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXnWZ2FbPzJiaILz	NH7mWHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|gzPyClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUAxNjB{OTFOwG0v	NHnYXJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
Sf9	NEHLcnhHfW6ldHnvckBie3OjeR?=			MlnhTY5pcWKrdHnvckBw\iClbH;u[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjB\|IN88UU4>	M4rCcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0PFM2Lz5zOUmxOFg{PTxxYU6=
Sf9	M3HW[2Z2dmO2aX;uJIF{e2G7		NVHOdXF[OSCqch?=	MXTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEirc{\4MZRi\2enZDDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFXMTXNCNCCLQ{WwJF0hOC5yMzFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV7NEi1PUc,OjB3OUS4OVk9N2F-
Sf9	MWHGeY5kfGmxbjDhd5NigQ>?		NXyyeJN[OSCqch?=	MU\Jcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gdoVkd22kaX7hcpQhUGm\|LYTh[4dm\CCHR1\SJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkh[2WubIOgZYZ1\XJiMTDodkBjgSCGRVzGTWEwfGmvZT3y[ZNwdH[nZDDmcJVwemmvZYTyfUBie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5N{W4PEc,OjJ{N{e1PFg9N2F-
Sf9	NEPYcZVHfW6ldHnvckBie3OjeR?=		NGjrTJYyOCCvaX7z	NYntVWRvUW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBifXSxcHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJGZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yMzFOwG0v	NUWyZZlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNVI2PDFpPkKyNVEzPTRzPD;hQi=>
Sf9	MWjGeY5kfGmxbjDhd5NigQ>?		NGnjPFEyKGi{	NYLpWmh3UW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IHP5eI9xdGG\|bXnjJIRwdWGrbjDv[kBGT0[UIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wN{DPxE1w	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4MUK3Nkc,OjJ\|NkGyO\|I9N2F-
Sf9	NYfk[VdWTnWwY4Tpc44h[XO\|YYm=		MlzCNUBpeg>?	M4DHV2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LpcYV1enliYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd4M{G0PEc,OjF5NkOxOFg9N2F-
Sf9	NGLBU2NHfW6ldHnvckBie3OjeR?=		NHPIZ2MyKGi{	NU\4TYRuUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJGVITlJiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{aX3leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEOg{txONg>?	M4Loe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEG2OVE4Lz5{MUixOlUyPzxxYU6=
Sf9	NVzIdW9iTnWwY4Tpc44h[XO\|YYm=			M4jmOWlvcGmkaYTpc44hd2ZiaHnzeIllcW6nLYTh[4dm\CC{ZXPvcYJqdmGwdDDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSC\|b3zp[E1xcGG\|ZTDFUGlUSSxiSVO1NEA:KDBwMEOg{txONg>?	M3rK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkK3OVk4Lz5{ME[yO\|U6PzxxYU6=
MIAPaCa2	M1r1SWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2TRPFQ5KGi{cx?=	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCPSVHQZWNiOiClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
MCF7	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYrsPYV{PDhiaILz	M2fMV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMzFOwG0v	Mk\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OVYoRjJ7NEC3PVU3RC:jPh?=
PC3	NIm2WGFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHntW2c1QCCqcoO=	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
Sf9	M{To[2Z2dmO2aX;uJIF{e2G7			NXj3[odTUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PDVvMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCnbor5cYUh[XW2b4Doc5NxcG:{eXzheIlwdiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOg{txONg>?	M37MZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
Sf9	NXvyWGpwTnWwY4Tpc44h[XO\|YYm=			MkH1TY5pcWKrdHnvckBw\iCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckAp[W2rbn:gZYNq\HNiNkS1JJRwKDFzOE[pJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h\W68eX3lJIF2fG:yaH;zdIhwenmuYYTpc44h[nliRFXMSmlCKHSrbXWgdoV{d2y4ZXSg[ox2d3KxbXX0dpktKEmFNUCgQUAxNjB\|IN88UU4>	M2jle\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkS1OVcxLz5{M{K0OVU4ODxxYU6=
A549	M17EZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{PzbFI1KGi{cx?=	NXn4emNKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlA{KM7:TT6=	NVvkSmdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVE{PjRpPkKzN\|kyOzZ2PD;hQi=>
Sf9	MV\GeY5kfGmxbjDhd5NigQ>?		MW[xNEBucW6\|	M1zLZmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCtaX7hd4Uh[3m2b4DsZZNucWNiZH;tZYlvKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIV5eHKnc4Ppc44hfmWldH;yMYlv\mWldHXkJIlve2WldDDz[lkh[2WubIOgZZN{\XO\|ZXSgZZMhdGW4ZXygc4Yh[XW2b4Doc5NxcG:{eXzheIlwdiCjZoTldkAyOCCvaX7zJIJ6KESHTF\JRU91cW2nLYLld49tfmWmIH\seY9zd22ndIL5MEBKSzVyIE2gNE4xOyEQvF2u	Ml3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK2OlAoRjJ\|OU[yOlYxRC:jPh?=
NCI-H292	NUTKW4RWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MW[3NkBpenN?	M3vQUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzQTJiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVkBi\nSncjC3NkBpenNiYomgcJVucW6nc3PlcoNmKGG\|c3H5MEBGSzVyIE2gNE4xOzFizszNMi=>	NELBcWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS1OVkyQSd-Mk[0OVU6OTl:L3G+
Sf9	MVfGeY5kfGmxbjDhd5NigQ>?		NGH3SoUyKGi{	NV3RUo1jUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCh4NEWgeI8hOTF6NjmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wN\|Ih\|ryPLh?=	NX6yZlRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QThpPkK0OlA4QTl6PD;hQi=>
Sf9	Moi2SpVv[3Srb36gZZN{[Xl?		MlzXNUBpeg>?	MXHJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiCleYTvdIxie22rYzDkc41icW5iKHHtbY5wKGGlaXTzJFY1PSC2bzCxNVg3MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yM{Kg{txONg>?	NEOyWXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNFQyOid-MkS2N\|A1OTJ:L3G+
Sf9	MoH5SpVv[3Srb36gZZN{[Xl?		MlnYNVAhdWmwcx?=	M{fscmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCleYTvdIxie22rYzDkc41icW5iKE[0OUB1dyBzMUi2LUApfW6tbn;3ckBwemmpaX6pJIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxNEBucW6\|IH\vcIxwf2WmIHL5JGFVWC2PZ1PsNkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODN{IN88UU4>	MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNES4OVQoRjJ2MUS0PFU1RC:jPh?=
A431	MWjGeY5kfGmxbjDhd5NigQ>?			M3rXTmlvcGmkaYTpc44hd2ZiRVfGVkBqdnS{YXPlcIx2dGG{IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNEOxJINmdGy\|IHL5JGVNUVODLDDJR\|UxKD1iMD6wN\|Qh\|ryPLh?=	NX;Kdog2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTVpPkKwN\|Q3PjV3PD;hQi=>
A549	MlvtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXi0PEBpenN?	Ml6wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB2IN88UU4>	M1rINlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
B16/F10	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEjpdJk1QCCqcoO=	NH\1dYVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOk9HOTBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODVizszNMi=>	NXT0TpJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU5ODJpPkKzNlQ2QDB{PD;hQi=>
MIAPaCa	NWHPe41rTnWwY4Tpc44h[XO\|YYm=			MVXJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3JRXBiS2FiY3XscJMh[nliRVzJV2EtKEmFNUCgQUAxNjB3MTFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODhzN{WyN{c,OjB6MUe1NlM9N2F-
A431	Mn\DR5l1d3SxeHnjbZR6KGG\|c3H5		NUHBVopDPDhiaILz	NH:xSlFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYKg[ZhxemW\|c3nu[{BGT0[UIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC1OUDPxE1w	NYWyRYhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NVQ3OTJpPkKyOFE1PjF{PD;hQi=>
Sf9	M3f0ZWZ2dmO2aX;uJIF{e2G7			NYe3NJBiUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuLXzlcod1cCCJU2SteIFo\2WmIHj1cYFvKEJvUlHGJHY3ODCHIH31eIFvfCBqNEG3JJRwKDd4NjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKEKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5iTVXLNUBieyC\|dXLzeJJifGViYomgUpUueGGpZTDn[Ywu[mG\|ZXSgdIhwe3Cqb4Kgd4Nz\WWwIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wOkDPxE1w	M{PGdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUS5PFQyLz5{OUW0PVg1OTxxYU6=
Sf9	Mn2xSpVv[3Srb36gZZN{[Xl?		MoXQNVAhdWmwcx?=	NWG2Z3ZIUW6qaXLpeIlwdiCxZjDIbZM3NXSjZ3fl[EBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApfW6tbn;3ckBwemmpaX6pJEg3PDVidH:gNVE5PiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoLUmgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KG[xbHzve4VlKGK7IFHUVEBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yNjFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO1N{c,Ojh2M{GzOVM9N2F-
MCF7	MlLZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmToOFghcHK\|	NH\S[olCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFch\|ryPLh?=	M{TkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{[xNlczLz5{MkO2NVI4OjxxYU6=
PC9	M4W3U2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1\KZ\|k3KGi{cx?=	NUnac4ljSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|kh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IGP5eI95KGe{ZXXuJI1iemuncjDiZZNm\CCobIXvdoV{[2WwY3WgZY5idHm\|aYOsJGlEPTBiPTCwMlA4KM7:TT6=	NV3sXIVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
LoVo	M3T2eGZ2dmO2aX;uJIF{e2G7		MkXXNkBpenN?	M1XrS2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xPzdizszNMi=>	NHKyTno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzNFk6PCd-MkO5N\|A6QTR:L3G+
HepG2	MkLvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWjmPYxsPDhiaILz	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC4JO69VS5?	NFHnTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixOlUyPyd-MkG4NVY2OTd:L3G+
MCF7	M1nSUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXi0PEBpenN?	NGfs[IZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFgh\|ryPLh?=	NGHVS4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm4PFYzPCd-Mki5PFg3OjR:L3G+
Sf9	NVnO[XNLTnWwY4Tpc44h[XO\|YYm=		NH;sWGEyOCCvaX7z	MYnJcohq[mm2aX;uJI9nKEirc{[teIFo\2WmIFXHSnIhMHWwa37ve44hd3KrZ3nuLUBkgXSxcHzhd41q[yCmb33hbY4h\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSCrboPlZ5Qh[2WubIOgZYZ1\XJiMUCgcYlveyCob3zsc5dm\CCkeTDh[IRqfGmxbjDv[kBCXFBvTXfDcFIh[W6mIH3lZZN2emWmIHHmeIVzKDFiaIKgZpkhfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB6IN88UU4>	M4W3clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
Sf9	M{O2OWZ2dmO2aX;uJIF{e2G7			NILJ[WlKdmirYnn0bY9vKG:oIFjpd{03KHSjZ3fl[EBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApPjR3IITvJFEyQDZicnXzbYR2\XNrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDj[YxteyCkeTDkbZN{d2OrYYTpc44u\W6qYX7j[YQhdGGwdHjhcoll\SCobIXvdoV{[2WwY3WgbY1ufW6xYYPzZZkwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB6IN88UU4>	NFK1dJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0PVg1OSd-Mkm1OFk5PDF:L3G+
MCF7	M1zrO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWeyOEBpenN?	MkDLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC4JO69VS5?	M1K1W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{mxN\|Y1Lz5{M{O5NVM3PDxxYU6=
BA/F3	NHXmT2RHfW6ldHnvckBie3OjeR?=		MYi0PEBpenN?	M1ryWGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6UjDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEmFNUCgQUAxNjB6NzFOwG0v	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ\|NUi0NUc,Ojd{M{W4OFE9N2F-
Sf9	MlLiSpVv[3Srb36gZZN{[Xl?		NIG5S3c2KG2rboO=	NEPmd3NKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFfTWE11[WepZXSgTGVTOiBqNke2MYVv\CliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMheHKnaX7jeYJifGWmIH\vdkA2KG2rboOg[o9tdG:5ZXSgZpkhSVSSIHHk[Il1cW:wIHHu[EBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|IHL5JGhVWkZiYYPzZZktKEmFNUCgQUAxNjB7MTFOwG0v	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7NkW4NEc,OzByOU[1PFA9N2F-
A431	NE\pZZFEgXSxdH;4bYNqfHliYYPzZZk>		M3T4ZVczKGi{cx?=	NGPSXm5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v	Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEi3OlEoRjF7OEi4O\|YyRC:jPh?=
B16F10	NHTGV49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXjoUoluPDhiaILz	NF7QbFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOmYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4MUK3Nkc,OjJ\|NkGyO\|I9N2F-
MCF7	NV3kOnlmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnqwNVIhcHK\|	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOTJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	NImzR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlQ5Oid-Mk[2OVI1QDJ:L3G+
A549	NGnn[WVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Ml;jOFghcHK\|	M{DKT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	NWD3dpNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
HepG2	NX7MN4ZySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWe0PEBpenN?	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGg{txONg>?	NVnieHZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
Sf9	MnzRSpVv[3Srb36gZZN{[Xl?			M{W2R2lvcGmkaYTpc44hd2ZiaIXtZY4h[2yxbnXkJGhGWjJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IHL5JJNwdGmmLYDoZZNmKEWOSWPBMEBKSzVyIE2gNE4yOiEQvF2u	Mn;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|coRjF7OUG0PFM4RC:jPh?=
HepG2	M1e2ZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWfSe3M1PDhiaILz	NXnSdYtsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NIHWUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
B16F10	NWLnOHBCSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnOzOFghcHK\|	NELtcoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOmYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	M2\5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUi4OlI1Lz5{OEm4PFYzPDxxYU6=
HepG2	M{L5emFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mly5OFghcHK\|	NIjpSVhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEzKM7:TT6=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{m5PEc,OjR4MEe5PVg9N2F-
HepG2	Ml7GRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NULremRyPDhiaILz	NIWzTVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEzKM7:TT6=	NFL3N4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNFQyOid-MkS2N\|A1OTJ:L3G+
HepG2	NYPUNFBLS3m2b4TvfIlkcXS7IHHzd4F6		MnTnOFghcHK\|	M3L0eGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	NHjTTlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0OFg2PCd-MkSxOFQ5PTR:L3G+
HepG2	NFXvepdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHzuOWsyOiCqcoO=	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDF{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
HepG2	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWS0PEBpenN?	NIq5Z5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEzKM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUW3NEc,OjN{NEW1O\|A9N2F-
HepG2	NUnGWlJXSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmHIOFghcHK\|	M1jOUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK2OlAoRjJ\|OU[yOlYxRC:jPh?=
U251	MljWSpVv[3Srb36gZZN{[Xl?			M1XzZ2lvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYomgdIhwe3Cqb4T5do9{cW6nIFXMTXNCKGG\|c3H5MEBKSzVyIE2gNE4yOjR5IN88UU4>	MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
U251	Ml;0SpVv[3Srb36gZZN{[Xl?		MkK3OlAhdWmwcx?=	MXPJcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDDWSWdHWjJiYXP0bZZifGmxbjDpckBpfW2jbjDVNlUyKGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNiZn;scI94\WRiYomgWmVITiCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDBwMUK0O{DPxE1w	M4TY[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm4PFY6Lz5\|MEC5PFg3QTxxYU6=
U251	M4\wdmZ2dmO2aX;uJIF{e2G7		M3rBU\|YxKG2rboO=	MUPJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCqdX3hckBWOjVzIHPlcIx{KGOxbYDveY5lKHC{ZYTy[YF1\WRiZn;yJFYxKG2rbjDi[YZwemViVlXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RibXX0bI9lNCCLQ{WwJF0hOC5zMkS3JO69VS5?	NWfYXoRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFI2OTlpPkK1PFgzPTF7PD;hQi=>
A549	MmHIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3jVb\|Q5KGi{cx?=	MlvZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGzJO69VS5?	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe5PVgoRjJ2NkC3PVk5RC:jPh?=
A549	NELhOlJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUjPSJpDPDhiaILz	MoXTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGzJO69VS5?	NXjJXI5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|A1OTJpPkK0OlMxPDF{PD;hQi=>
A549	NXzpd257S3m2b4TvfIlkcXS7IHHzd4F6		M1\Xe\|Q5KGi{cx?=	NYLodoxLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2NEi1OEc,OjRzNES4OVQ9N2F-
A549	MlflRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4\OZlQ5KGi{cx?=	NGi2cIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVMh\|ryPLh?=	M{\CWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[yOlYxLz5{M{m2NlY3ODxxYU6=
HCT116	NX7zcmxPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVjtdodZPDhiaILz	M17SfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE1KM7:TT6=	NUDxcVFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
DIFI	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=		NIPleow1KGSjeYO=	MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDETWZKKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IECuNVQh\|ryPLh?=	M2LqbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
Sf9	MlnHSpVv[3Srb36gZZN{[Xl?		NIfhXI4yKGi{	MnfHTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKGi3bXHuJJJm[2:vYnnuZY51KGO7dH;wcIF{dWmlIHTvcYFqdiCxZjDISXIzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nliRFXMSmlCN3SrbXWtdoV{d2y4ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5zNDFOwG0v	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4MUK3Nkc,OjJ\|NkGyO\|I9N2F-
Sf9	NVrpR\|gzTnWwY4Tpc44h[XO\|YYm=			M1q2bWlvcGmkaYTpc44hd2ZiaIXtZY4h[2yxbnXkJGhGWjJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IHL5JJNwdGmmLYDoZZNmKEWOSWPBMEBKSzVyIE2gNE4yPiEQvF2u	M4[xXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0PFM2Lz5zOUmxOFg{PTxxYU6=
Sf9	MmLwSpVv[3Srb36gZZN{[Xl?		NEXTb4UyKGi{	MmHyTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYO2fE11[WepZXSgTGVTOiCjdYTvdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDFUGlUSSxiSVO1NEA:KDBwMU[g{txONg>?	M{\4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
Sf9	M1mzWmZ2dmO2aX;uJIF{e2G7		MnTzNUBpeg>?	NGnNbW5KdmirYnn0bY9vKG:oIHH1eI9xcG:\|cHjvdplt[XSrb36gc4YhcHWvYX6gTGVTOiCleYTvdIxie22rYzDkc41icW5iKHHtbY5wKGGlaXTzJFY4PiC2bzCxNlQ2MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5zNjFOwG0v	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MESxNkc,OjR4M{C0NVI9N2F-
Sf9	MWnGeY5kfGmxbjDhd5NigQ>?			NYDsZZk1UW6qaXLpeIlwdiCxZjDoeY1idiCKRWKyJIN6fG:ybHHzcYlkKGSxbXHpckAp[W2rbn:gZYNq\HNiNke2JJRwKDF{NEWpJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYomgSGVNTkmDIITpcYUhemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkG2JO69VS5?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
B16F10	NVzOR4k5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MV2xNkBpenN?	MoPhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEMU\GNVAh[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVch\|ryPLh?=	NIfvUZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlQ5Oid-Mk[2OVI1QDJ:L3G+
HeLa	NVX2ToVjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIPlTWEyOiCqcoO=	M3PhV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiBzMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	M3[xXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyOFgzLz5{Nk[1NlQ5OjxxYU6=
Sf9	NGTXeFhHfW6ldHnvckBie3OjeR?=			MnPqTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKHKnY3;tZolv[W62IFjFVlIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCnbor5cYUh[XW2b4Doc5NxcG:{eXzheIlwdiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMjFOwG0v	M1LwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
A16-F10	NInIVldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX61fmJ2PDhiaILz	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEFzNj3GNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNkDPxE1w	MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NEW1O\|AoRjJ\|MkS1OVcxRC:jPh?=
MDA-MB-468	M{i0e2N6fG:2b4jpZ4l1gSCjc4PhfS=>			NHqwPG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1emmybHWgcoVo[XSrdnWgUWRCNU2ELUS2PEBk\WyuczygTWM2OCB;IECuNlM2OiEQvF2u	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
CAL27	NVji[lFRS3m2b4TvfIlkcXS7IHHzd4F6		MU[0JIRigXN?	NXPw[Y91S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5{M{mg{txONg>?	M4Xm[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
Sf9	MonpSpVv[3Srb36gZZN{[Xl?		M2fhdFUhdWmwcx?=	NWHlR2FGUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHZGT0[UIDi3PFku\W6mKTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDVibXnud{Bnd2yub4fl[EBjgSCDVGCgZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhUFSURjDhd5NigSxiSVO1NEA:KDBwMkWg{txONg>?	M2rHUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm2OVgxLz5\|MEC5OlU5ODxxYU6=
A549	MnzlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF7ISHk1QCCqcoO=	NVrUbGJLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHLhd4FtKGOnbHyg[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK3JO69VS5?	NWHxTGd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OlMyPDhpPkKxO\|Y{OTR6PD;hQi=>
T24 NIH	MkjSSpVv[3Srb36gZZN{[Xl?			MX\Jcohq[mm2aX;uJI9nKGyrZ3Hu[EB{fGmvdXzheIVlKGW{YlKyJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iVEK0JG5KUCClZXzsd{whUUN3MDC9JFAvOjl7IN88UU4>	MnTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2OECyPFQoRjF4NEiwNlg1RC:jPh?=
GXF251L	MoezR5l1d3SxeHnjbZR6KGG\|c3H5		NHfLR2E1KGSjeYO=	M17VdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdZTjJ3MVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5\|Nkmg{txONg>?	MojyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
A431	M2HP[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFLW[ZA4OiCqcoO=	NV3aTG5ySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlQxQSEQvF2u	NX\1bI51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFM4PDJpPkK0NVg{PzR{PD;hQi=>
MDA-MB-231	NVXpUVIzS3m2b4TvfIlkcXS7IHHzd4F6			M13Cd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJRzcXCuZTDu[YdifGm4ZTDNSGEuVUJvMkOxJINmdGy\|LDDJR\|UxKD1iMD60N\|g2KM7:TT6=	NHP3VVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFY2Oid-MkS4PVA3PTJ:L3G+
A431	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXm3NkBpenN?	Mn\LS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjR5IN88UU4>	M2HsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUizO\|Q2Lz5zN{m4N\|c1PTxxYU6=
BA/F3	M2D5XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MY[5OkBpenN?	NUjZWXVOT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEGgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
BA/F3	NEHYN5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIXmN3c6PiCqcoO=	NY\aZYdFT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEOgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{MkK3N\|MoRjJyMkKyO\|M{RC:jPh?=
BA/F3	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEnCfmw6PiCqcoO=	NIXt[21Iem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTGWuNTDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	MnntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{MkK3N\|MoRjJyMkKyO\|M{RC:jPh?=
BA/F3	MoTpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnrNPVYhcHK\|	NWfSd2ZsT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDDh[pRmeiB7NjDodpMh[nliY3XscEB1cXSncj3ncI8h[XO\|YYmsJGdKPTBiPTCwMlUh\|ryPLh?=	M2TPZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkKyO\|M{Lz5{MEKyNlc{OzxxYU6=
Huh7.5	NELlfpRCdnSrdnnyZYwh[XO\|YYm=		M{fGVVczKGi{cx?=	NIPCc4xCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSyC4aYL1d{BLPi:MRligbY5n\WO2ZXSgbY4hcHWvYX6gTJVpPy53IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44hdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNTFOwG0v	NW\tO4JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlI4OzlpPkK1PFIzPzN7PD;hQi=>
Huh7.5	NUOySW06SW62aY\pdoFtKGG\|c3H5		MofjO\|IhcHK\|	MWjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDI[ZBifGm2aYOgR{B3cXK3czDKOk9LTkhiZXzlZ5Rzd3CxcnH0[YQhcW5iaIXtZY4hUHWqNz61JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaX70doFk\WyudXzhdkBqdm[nY4Tpeol1gSCmcoXnJJRz\WG2ZXSg[ZZmenliMkSgbJJ{KG[xcjC3NkBpenNibXXhd5Vz\WRiN{KgbJJ{KHCxc4Sg[Yxm[3S{b4DvdoF1cW:wIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNTFOwG0v	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh{MkezPUc,OjV6MkK3N\|k9N2F-
Huh7.5	Mn6zRY51cX[rcnHsJIF{e2G7		NXm0WJNkPzJiaILz	Mnj5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGMhfmm{dYOgTlYwUk[KIHnu[oVkfGWmIHnuJIh2dWGwIFj1bFcvPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV5fHKjY3XscJVt[XJiaX7m[YN1cX[rdImg[JJ2\yC2cnXheIVlKGW4ZYL5JFI1KGi{czDmc5IhPzJiaILzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjVizszNMi=>	NEP3VYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiyNlc{QSd-MkW4NlI4Ozl:L3G+
HEK293	NH7zUJRHfW6ldHnvckBie3OjeR?=		NULOUHNiPSCvaX7z	NYLNblRbUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMlKxJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCdM1jdSVNUKHWydHHr[UBqdmO3YnH0[YQh\m:{IEWgcYlveyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvPTNizszNMi=>	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293	MXLGeY5kfGmxbjDhd5NigQ>?		NX:5PJFyPSCvaX7z	NHzPUGlKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFB{QkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFt\|SG3FN3MhfXC2YXvlJIlv[3WkYYTl[EBnd3JiNTDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjV3IN88UU4>	NHexSnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
A431	NV\qV41LSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoLUO\|IhcHK\|	MonCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlU3KM7:TT6=	M2C4UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[1PVY6Lz5{NEW2OVk3QTxxYU6=
MDA-MB-435	NWjLSZRyS3m2b4TvfIlkcXS7IHHzd4F6			M3\NOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N\|Uh[2WubIOsJGlEPTBiPTCwMlYzOjFizszNMi=>	NVPxN2dERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
LXFA 629L	NGTWbVNEgXSxdH;4bYNqfHliYYPzZZk>		MX20JIRigXN?	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDZ{OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC54NjFOwG0v	M4LmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
A549	M2nqUGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWeyOEBpenN?	NUT2dXYzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC55MzFOwG0v	Mln2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyMki1N\|QoRjJ7MEK4OVM1RC:jPh?=
A431	NUDBVVdXS3m2b4TvfIlkcXS7IHHzd4F6		Mkf2O\|IhcHK\|	MkHVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuO\|Uh\|ryPLh?=	NUCzR4dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVEyOjNpPkK0OFEyOTJ\|PD;hQi=>
A431	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MV:3NkBpenN?	NFSw[mpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE45PDRizszNMi=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR6N{mxO{c,OjZ2OEe5NVc9N2F-
A431	MojYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVfMOnVCPzJiaILz	MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlkyPSEQvF2u	NFPVbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
Calu3	NW\ic4pYS3m2b4TvfIlkcXS7IHHzd4F6		MYm3NkBpenN?	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuPVMh\|ryPLh?=	NHjiVIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
DU145	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		NEPvTI01KGSjeYO=	NEfXXI9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjl4NjFOwG0v	M4PYNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
NCI-H2122	NFXXRohCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			M2rldGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOTJ{IHPlcIx{NCCLQ{WwJF0hOSEQvF2u	M{THVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
NCI-H292	M{\F[WN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{C3e\|czKGi{cx?=	Ml3WR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh{OUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDFizszNMi=>	M122OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG1PFU3Lz5{NUKxOVg2PjxxYU6=
A431	NIDF[JBHfW6ldHnvckBie3OjeR?=		MlrGNVAhdWmwcx?=	MnnZTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEGwJI1qdnNiYomgSmxKW0FuIFnDOVAhRSBzLkKg{txONg>?	M1TKVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNECzO\|AxLz5{MESwN\|cxODxxYU6=
A431	NVXE[XV5TnWwY4Tpc44h[XO\|YYm=			NYnDN5hDUW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCrbjDoeY1idiCDNEOxJINmdGy\|LDDJR\|UxKD1iMT6yJO69VS5?	Mk\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwO\|IoRjJyNUW4NFczRC:jPh?=
A431	NEnD[GxHfW6ldHnvckBie3OjeR?=		M13UUFYxKG2rboO=	NEHr[I5KdmirYnn0bY9vKG:oIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFkfGm4aYT5JIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIFG0N\|Eh[2WubIOgZYZ1\XJiNkCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDFwMjFOwG0v	MoPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MES3OFEoRjJ{MkC0O\|QyRC:jPh?=
A431	NGrJZWtHfW6ldHnvckBie3OjeR?=		NHX0b2g3OCCvaX7z	NV2xe\|hpUW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNEOxJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKgdJJmfHKnYYTl[EBnd3JiNkCgcYlveyCycnnvdkB1dyCHR1[gZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDwbI9{eGixdInyc5NqdmViRVzJV2Eh[3m2b3Lsc5Qh[W6jbInzbZMtKEmFNUCgQUAyNjJizszNMi=>	M1XFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e1NFkxLz5{M{O3OVA6ODxxYU6=
A431	M123[2Z2dmO2aX;uJIF{e2G7		M2HrflYxKG2rboO=	NULoUnNOUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDD0fZJwe2mwZTDwbI9{eGixconsZZRqd25iaX7jeYJifGWmIH\vdkA3OCCvaX7zJJBzcW:{IITvJGVITi2jY4TpeoF1cW:wIH3lZZN2emWmIEGwJI1qdnNiYomgSWxKW0FuIFnDOVAhRSBzLkKg{txONg>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR\|NEGzPUc,OjN2M{SxN\|k9N2F-
A431	MWXGeY5kfGmxbjDhd5NigQ>?		MYe2NEBucW6\|	NWC0Oow1UW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNicILleJJm[XSnZDDmc5IhPjBibXnud{Bu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFXMTXNCNCCLQ{WwJF0hOS5{IN88UU4>	Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5M{mwPVAoRjJ{N{O5NFkxRC:jPh?=
H9	NX20bIVjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYT4S2k3PzJiaILz	Mn;nRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKOTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NEA:KDFwMzFOwG0v	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
PC9	MkjySpVv[3Srb36gZZN{[Xl?		MYmyOEBpenN?	Mn7ETY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NEA:KDFwM{[g{txONg>?	M4q1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUiwNlE5Lz5{Mkm4NFIyQDxxYU6=
SK-BR-3	NGTuWpRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NE\FZmlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMWJTNTNiY3XscJMh[W[2ZYKgbJJ{KGK7IFHUVEBkd262ZX70JIF{e2G7LDDJR\|UxKD1iMT61OkDPxE1w	NXXzdJZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
LXFA 289L	M1raOGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NInOeXg1KGSjeYO=	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDJ6OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOS55ODFOwG0v	M2TzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
SCC15	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M{DjOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1PDNVUh[2WubIOsJGlEPTBiPTCxMlk1KM7:TT6=	NFLkXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
Jurkat	NHX6Z25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoPBNlQhcHK\|	NUeycVNJT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUnW{a3H0JINmdGy\|IHHmeIVzKDJ2IHjyd{whUUN3MDC9JFIh\|ryPLh?=	M2nYNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
erythroleukemia cell	MnnFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYKyOEBpenN?	M4Lkb2dzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaIXtZY4h\XK7dHjyc4xmfWunbXnhJINmdGy\|IHHmeIVzKDJ2IHjyd{whUUN3MDC9JFIh\|ryPLh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
erythroleukemia cell	NEXCXWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFy5bWEzPCCqcoO=	M1OyfWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	MoPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
NCI-H1993	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		M{G2RVQ5KGi{cx?=	NH\XSWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5PVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFQ{KM7:TT6=	NVXNXIVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
HT-29	NIXrcllCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYi3NkBpenN?	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIIXu[IVzKG6xcn3vfIliKGOxbnTpeIlwdnNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDJwOUig{txONg>?	NGnrdoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2PFA1PCd-MkW0OlgxPDR:L3G+
PANC1	M4XTVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWC3NkBpenN?	M4fTVmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNzIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDNwMTFOwG0v	NH6zcGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW0O\|Y6OCd-Mk[1OFc3QTB:L3G+
SCC25	NUTLUYNQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M1TRS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1PDNlUh[2WubIOsJGlEPTBiPTCzMlM1KM7:TT6=	MoXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
NCI-H358	M121XWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4LDUlQ5KGi{cx?=	Mm\qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFM2QCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KGOla{igZZN{[XluIFnDOVAhRSB\|LkmxJO69VS5?	NH:yeVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{KzOFg5Pyd-MkeyN\|Q5QDd:L3G+
COS7	NWTRcJJpTnWwY4Tpc44h[XO\|YYm=			NIHWeFlKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\CCrbjDDU3M4KGOnbHzzMEBKSzVyIE2gOEDPxE1w	MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
L3.6PL	NFWyOlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUjGUZF5PzJiaILz	M2\JNGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGw{Nj[STDDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB2IN88UU4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV2N{[5NEc,OjZ3NEe2PVA9N2F-
HT-29	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M37TZVczKGi{cx?=	NX;0PWl5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckB2dmSncjDofZBwgGmjIHPvcoRqfGmxboOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IESuN\|ch\|ryPLh?=	NX2xXmo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlgxPDRpPkK1OFY5ODR2PD;hQi=>
OVCAR3	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWC3NkBpenN?	NGLnUIlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFQvPiEQvF2u	Mm[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OUm1N\|IoRjJ4NUm5OVMzRC:jPh?=
Calu3	M1jCbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXK3NkBpenN?	NGHJfZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhcJU{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFQvPyEQvF2u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
hematopoietic progenitor cell	Mlq5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M1vRSWdzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaHXtZZRweG:rZYTpZ{Bxem:pZX7peI9zKGOnbHzzJIl{d2yjdHXkJIZzd21icH;sfYN6fGinbXnhJJZmemFicHH0bYVvfCCkeTDjc4xwdnliZn;ycYlv\yCjc4PhfUwhUUN3MDC9JFUh\|ryPLh?=	NF22bY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G3PFczOid-MUexO\|g4OjJ:L3G+
KB	NEe0U\|BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF\QZmE1QCCqcoO=	M2DkcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKGGwZDDTdoMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFUh\|ryPLh?=	NVLPcoZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPFg3OjBpPkK2NVg5PjJyPD;hQi=>
N87	M1LsW2Z2dmO2aX;uJIF{e2G7			NUPYeXM4UW6qaXLpeIlwdiCxZjDFdoJDOiCrboTyZYNmdGy3bHHyJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDOPFch[2WubIOgZpkhTUyLU1GsJGlEPTBiPTC1MlIh\|ryPLh?=	NFX1OYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2PSd-MkCzOFY3PTV:L3G+
NCI-H1975	NHrMWmtEgXSxdH;4bYNqfHliYYPzZZk>		NV3GRYU3PzJiaILz	NVewZYN1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIV5eHKnc4PpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuOVEh\|ryPLh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMUGyN{c,OjR2MUGxNlM9N2F-
MRC5	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEjhbGw4OiCqcoO=	M2DBSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEWuPEDPxE1w	NWTNO4NYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
HepG2	NGjINVVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{TyNVQ5KGi{cx?=	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3Lkig{txONg>?	MofXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFgoRjJ4OEm2O\|A5RC:jPh?=
NCI-H358	NW\wbHJqSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|U5KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDZizszNMi=>	NG\aTo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
A549	MnHwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MkK3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJJZq[WKuZTDj[YxteyCjZoTldkA1QCCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDZwMk[g{txONg>?	M{n4[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe5N\|E1Lz5{Nki3PVMyPDxxYU6=
LNCAP	Mn2zR5l1d3SxeHnjbZR6KGG\|c3H5		MXm0JIRigXN?	NFTNXFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA3NjZ\|IN88UU4>	NHTZeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
MIAPaCa	M1yxR2Z2dmO2aX;uJIF{e2G7			M3TyPWlvcGmkaYTpc44hd2ZiRWLCZlIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG1KSVCjQ3GgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSB4LkezJO69VS5?	NEL4U5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEixO\|UzOyd-MkC4NVc2OjN:L3G+
NCI-H358	M{T2RmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NXjGW5pJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDN3ODDj[YxteyCjc4Pld5Nm\CCjczD2bYFjdGViY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA3Njh3IN88UU4>	NXHvOVRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O\|k{OTRpPkK2PFc6OzF2PD;hQi=>
NCI-H1975	M1PJSWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWO3NkBpenN?	NWew[W9ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNJI12fGGwdDDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNj65JO69VS5?	NGDLTmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4N\|c1Oid-MkSxPFM4PDJ:L3G+
NCI-H1975	MljpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2XEV\|czKGi{cx?=	NFP6UpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1z\XOrc4ThcpQhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC3MlA3KM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4NUm2PUc,OjR3NkW5Olk9N2F-
A549	NGPzcm9EgXSxdH;4bYNqfHliYYPzZZk>		NEjze481QCCqcoO=	M1PDTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFcvODl7IN88UU4>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
A549	MmjpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIjicJU1QCCqcoO=	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDjZ4s5KGG\|c3H5MEBKSzVyIE2gO{4{PSEQvF2u	M3Hab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkO0PFg4Lz5{N{KzOFg5PzxxYU6=
NCI-H1975	NXGzZpJ2S3m2b4TvfIlkcXS7IHHzd4F6		Mo\yOFghcHK\|	Mk\GR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB5LkS5PEDPxE1w	NIjsOWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
HCC827	NH;nbnRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NV3JfZdvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M5OjdiY3XscJMh[W[2ZYKgbJJ{KGK7IFHUVEBkd262ZX70JIF{e2G7LDDJR\|UxKD1iNz61JO69VS5?	M1PmclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
A549	Mk\0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1T5[VczKGi{cx?=	NX76XplESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJJVv\GW{IH7vdo1wgGmjIHPvcoRqfGmxboOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuOVkh\|ryPLh?=	NWXtZXNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlgxPDRpPkK1OFY5ODR2PD;hQi=>
BxPC3	NUC0cHpySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NGG5OoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
NCI-H1975	Mo\nSpVv[3Srb36gZZN{[Xl?		NEfOOW8zKGi{cx?=	NEfWVm9KdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{C5PVQoRjJ\|OUOwPVk1RC:jPh?=
PCI35	M3n2[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkDQO\|IhcHK\|	NH3NNVdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBRS0l\|NTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB5Lkeg{txONg>?	NVjvZYJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OFc3QTBpPkK2OVQ4PjlyPD;hQi=>
WM266.4	M1;n[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{DHdVI1KGi{cx?=	M4\5XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPE4xQSEQvF2u	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6NUm1O{c,OjJ7OEW5OVc9N2F-
WM266.4	M1\4U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1zZe\|I1KGi{cx?=	NV63bnZkT3Kxd4ToJIlvcGmkaYTpc44hcW5iaIXtZY4hX01{Nk[uOEBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJJJm\HWldHnvckBie3OjeTygS2k2OCB;IEiuNVIh\|ryPLh?=	M3TiUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUi1PVYzLz5{Mkm4OVk3OjxxYU6=
WM266.4	NYDufXpwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIHoSFUzPCCqcoO=	M4ewdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBIUTVyIE2gPE4yPCEQvF2u	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ\|OEi0NUc,Ojd{M{i4OFE9N2F-
H460	NWHrc4FjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh2NkCgZ4VtdHNiYX\0[ZIhcHK\|IHL5JGFVWCClb370[Y51KGG\|c3H5MEBKSzVyIE2gPE4zKM7:TT6=	NV;adpd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
OVXF 899L	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml\3OEBl[Xm\|	M1Ls[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XYEZiOEm5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB6Lke3JO69VS5?	NU\MU5J4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MCF7	NXjMOG9ISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3jESlI1KGi{cx?=	Mmf3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB6Lkm3JO69VS5?	NUfMXlNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PFU6PTdpPkKyPVg2QTV5PD;hQi=>
NCI-H1975	NXfZRXBPTnWwY4Tpc44h[XO\|YYm=		MXuyJIhzew>?	NXjpelJWUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMh[W[2ZYKgNkBpenNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSB7IN88UU4>	NV\sW\|ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
H1975	M3TSd2Z2dmO2aX;uJIF{e2G7		MXmyJIhzew>?	MWnJcohq[mm2aX;uJI9nKEWJRmKgWFc6OE1xTEi1PHIh\G:3YnzlJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iSEG5O\|Uh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTC5MlAxOyEQvF2u	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
A549	NUDk[JRiSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFTWPIE4OiCqcoO=	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25idX7k[ZIhcHmyb4jpZUBkd26maYTpc45{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA6NjFizszNMi=>	NG\6T2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2PFA1PCd-MkW0OlgxPDR:L3G+
H460	M3\UU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NWjWd5lLPzJiaILz	NVzzN25QS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hQS53IN88UU4>	NGLHelk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxOVg2Pid-MkWyNVU5PTZ:L3G+
PC9-DRH	NVPWT2g5TnWwY4Tpc44h[XO\|YYm=		M2rueVIhcHK\|	M4TyPGlvcGmkaYTpc44hd2ZiRVfGVkBl\WyndHnvck9VPzlyTTDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kuTFKKIHPlcIx{KGGodHXyJFIhcHK\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iOT63JO69VS5?	M{[4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
PC9-DRH	NYf4OIxVTnWwY4Tpc44h[XO\|YYm=		M{\zWVIhcHK\|	NXewdG0{UW6qaXLpeIlwdiCxZjDFS2ZTKFR5OUDNM4V5d25iMUmg[IVt\XSrb36gcZV1[W62IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCSQ{mtSHJJKGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyOCCvaX7zJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gPU44OzZizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6N{ezNEc,Ojh{OEe3N\|A9N2F-
U937	MkTrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUS3NkBpenN?	MkXzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOUO3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiYnz1[UBie3OjeTygTWM2OCB;IEmuPUDPxE1w	NIS4eY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
PAXF 546L	NELFWnVEgXSxdH;4bYNqfHliYYPzZZk>		MkPZOEBl[Xm\|	MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRXhHKDV2NlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOTBizszNMi=>	NFrr[WQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
RXF 486L	MlPGR5l1d3SxeHnjbZR6KGG\|c3H5		M37HV\|Qh\GG7cx?=	MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSXGYhPDh4TDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyOCEQvF2u	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
CAL27	NX2xW3BRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEODTEK3JINmdGy\|LDDJR\|UxKD1iMUCuNVUh\|ryPLh?=	NY\M[XlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SKHEP1	NFfFcWRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONSFXQNUBk\WyuczDh[pRmeiCqcoOgZpkhSVSSIHPvcpRmdnRiYYPzZZktKEmFNUCgQUAyOC5\|NzFOwG0v	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
MDA-MB-468	Ml;XRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NVzaWGNISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy\|LDDJR\|UxKD1iMUGuOEDPxE1w	NHvDPIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SF539	MVjGeY5kfGmxbjDhd5NigQ>?		NX3l[5A3PjBibXnudy=>	MkDNTY5pcWKrdHnvckBw\iCSRFfGMWJDNWmwZIXj[YQhWESJRmKgZoV1[SCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hW0Z3M{mgZ4VtdHNib4\ldoV5eHKnc4PpcochWESJRmKgZoV1[SCycnX0doVifGWmIH\vdkA3OCCvaX7zJJBzcW:{IITvJHBFT0ZvQlKgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDwbI9{eGixdInyc5NqdmViRVzJV2Eh[3m2b3Lsc5Qh[W6jbInzbZMtKEmFNUCgQUAyOi5{IN88UU4>	NIS0PYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O3OVA6OCd-MkOzO\|UxQTB:L3G+
SF539	MnLvSpVv[3Srb36gZZN{[Xl?		MXy2NEBucW6\|	Mk\KTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiaX6gbJVu[W5iU1[1N\|kh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQSGdHWi2EQj3pcoR2[2WmIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdiCrbnP1ZoF1\WRiZn;yJFYxKG2rboOgdJJqd3JidH:gSWdHNWGldHn2ZZRqd25ibXXhd5Vz\WRiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDF{LkKg{txONg>?	M{\TZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEO0NVM6Lz5{M{SzOFE{QTxxYU6=
SF539	MlzZSpVv[3Srb36gZZN{[Xl?		M4XzPVYxKG2rboO=	NWP4TVJHUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgbY4hcHWvYX6gV2Y2OzliY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KEWOSWPBMEBKSzVyIE2gNVIvOiEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd\|OUC5NEc,OjJ5M{mwPVA9N2F-
A498	NXr2[YR[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXS0PEBpenN?	MnfsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzMj61JO69VS5?	MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyNUewOFIoRjJ7MEW3NFQzRC:jPh?=
NCI-H661	NFHhUGpEgXSxdH;4bYNqfHliYYPzZZk>		Mn;nOEB1dyB3IHThfZM>	NIrYeVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSE[2NUBk\WyuczDh[pRmeiB2IITvJFUh\GG7czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOi55MTFOwG0v	M4O5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
BT474	MkHBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYPjS3lwPzJiaILz	NGW2c3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFE{KM7:TT6=	NEnMOHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
BXF T24	MoTlR5l1d3SxeHnjbZR6KGG\|c3H5		MVu0JIRigXN?	NIL4N49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDYEZiVEK0JINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDF\|Lkmg{txONg>?	M{POWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
CXF 269L	NE\NT2xEgXSxdH;4bYNqfHliYYPzZZk>		MUW0JIRigXN?	MkLHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR3hHKDJ4OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOTZizszNMi=>	NYDvXnVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
HEK293	NFrndWRHfW6ldHnvckBie3OjeR?=		M3THTlIhdWmwcx?=	M17BbWlvcGmkaYTpc44hd2ZiaIXtZY4hV0OWMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHWydHHr[UBw\iCDU2CrJIFnfGW{IEKgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCxOk4zKM7:TT6=	NVHIPW9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyN\|A6QDVpPkK4NlMxQTh3PD;hQi=>
PC3M	NGWzcXdEgXSxdH;4bYNqfHliYYPzZZk>		NGn0[FY1KGSjeYO=	NV6zSmZFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|TTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyPy5{IN88UU4>	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
A549	NFOzfIdCdnSrY3HuZ4VzKGG\|c3H5		MUK5OkBpenN?	NIrwN4hCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF5LkOyJO69VS5?	NUWwNop4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFk5PDFpPkK5OVQ6QDRzPD;hQi=>
LXFL 529L	MkfOR5l1d3SxeHnjbZR6KGG\|c3H5		NIrydnM1KGSjeYO=	M1zwfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkxiNUK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzNz60JO69VS5?	MorXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
FADU	M4e4ZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[DRGWgZ4VtdHNuIFnDOVAhRSBzODFOwG0v	NGrpUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
LNCAP	NXKyOpFrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NWjSZlNYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{whUUN3MDC9JFE5NjN3IN88UU4>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
LO2	NFjMfJREgXSxdH;4bYNqfHliYYPzZZk>		MmPtOFghcHK\|	NIrXZY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVzJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE5NjVizszNMi=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh7NkewPEc,OjZ6OU[3NFg9N2F-
MEXF 276L	NUDjWFg2S3m2b4TvfIlkcXS7IHHzd4F6		MmrjOEBl[Xm\|	NUi0enZuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUW[RjCyO\|ZNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEG4MlYh\|ryPLh?=	MoPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
DU145	NE\Ub4pEgXSxdH;4bYNqfHliYYPzZZk>		NEfS[pM1KHSxIEWg[IF6ew>?	M3qybGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQhfG9iNTDkZZl{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG5MlQh\|ryPLh?=	NFnXbYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2OlU2PSd-MkC0OlY2PTV:L3G+
MCF7	M33hZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnX5OFghcHK\|	M2jnUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkCg{txONg>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB2N{SxNEc,OzByNEe0NVA9N2F-
Saos2	M1TZVWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1LuO\|Qh\GG7cx?=	MlXwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV4FwezJiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNlEh\|ryPLh?=	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
HEK293	MYnGeY5kfGmxbjDhd5NigQ>?			NWraVVRDUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMVKxJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHMUetZoV1[UdidYD0ZYtmKGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAzOSEQvF2u	NIK5eZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
HEK293	Mm\JSpVv[3Srb36gZZN{[Xl?			M4myVmlvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDGEMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTTF5LXLleIFIKHWydHHr[UBjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IEKxJO69VS5?	NWDCNlJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
A549	MoXERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGHyTng4OiCqcoO=	NFXrWJlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKxMlMh\|ryPLh?=	Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6OE[1NFkoRjJ6OEi2OVA6RC:jPh?=
H460/Vbl	M2rQdGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWm3NkBpenN?	MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxN1[kbDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOjFwNTFOwG0v	M3PQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG1PFU3Lz5{NUKxOVg2PjxxYU6=
UXF 1138L	M16xZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3;N[FQh\GG7cx?=	NVLRZodTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXViIIEGxN\|hNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEK0MlUh\|ryPLh?=	M4jHc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
MAXF 401NL	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=		MUG0JIRigXN?	M1j2fmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1CYEZiNECxUmwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMkWg{txONg>?	M4fubFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
HepG2	NEey[mlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mm\sOFghcHK\|	MlPVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkWg{txONg>?	MlXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNEe0NVAoRjNyMES3OFExRC:jPh?=
HepG2	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		MYqyOEBpenN?	MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUCgQUAzPSEQvF2u	NF\MRZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES4O\|EzPyd-Mki0PFcyOjd:L3G+
HuH7	NWD2UYxNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGPFVGk1QCCqcoO=	M4nX[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkWg{txONg>?	NU\WTFdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
A498	M{CxSGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYO0PEBpenN?	M{PM[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO\|aX7nJGVITlJiYX7kJHNz[yCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOjVwNjFOwG0v	M4j6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi4OlIxLz5{NkG4PFYzODxxYU6=
MEXF 1341L	NVT0c3VRS3m2b4TvfIlkcXS7IHHzd4F6		NVfSWm5{PCCmYYnz	M33rWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GYEZiMUO0NWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{CuNUDPxE1w	M3;iXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
MDA-MB-231	NYHhfm42SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NI\HNoM4OiCqcoO=	M3TEcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{OC5zMjFOwG0v	M1rnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUKzN\|g{Lz5{OEmyN\|M5OzxxYU6=
PXF 1752L	M2\xOGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3PnSFQh\GG7cx?=	MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQXGYhOTd3MlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOzFwNjFOwG0v	NUTZUGoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
A549	NEDD[I5EgXSxdH;4bYNqfHliYYPzZZk>		NFyz[mU1KHSxIEWg[IF6ew>?	NW\MO4NDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1KHSxIEWg[IF6eyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzN{4xOyEQvF2u	NGq3[m49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2OlU2PSd-MkC0OlY2PTV:L3G+
MDA-MB-231	NIj3c5ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHTOUHk1QCCqcoO=	NUPWS3VwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDN\|LkS2JO69VS5?	M3vTR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUKzN\|g{Lz5{OEmyN\|M5OzxxYU6=
MDA231	MlfxR5l1d3SxeHnjbZR6KGG\|c3H5		NGLjUFQ1KGSjeYO=	NX3DN4VKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDMkOxJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDN2LkWg{txONg>?	MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
LXFL 1121L	NVP5ZWJJS3m2b4TvfIlkcXS7IHHzd4F6		MVi0JIRigXN?	M4HpXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkxiMUGyNWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{SuOkDPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
PXF 698L	NX3rT3NoS3m2b4TvfIlkcXS7IHHzd4F6		MWC0JIRigXN?	NUL2OY5[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWFiIIE[5PGwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{[uOEDPxE1w	M{GyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
PC3	Mni5R5l1d3SxeHnjbZR6KGG\|c3H5		M3nlTVQhfG9iNTDkZZl{	Mnv6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IESgeI8hPSCmYYnzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDN4Lke2JO69VS5?	NVn4N\|VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
HEK293	MoXWSpVv[3Srb36gZZN{[Xl?		NUW0UmRRPSCvaX7z	Mke3TY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJ\|IHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBcO0ifRUG3MYJmfGGJIIXweIFs\SCrbnP1ZoF1\WRiZn;yJFUhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDRzIN88UUwhUUN3MDC9JFQ1KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
RXF 393NL	NF3v[4pEgXSxdH;4bYNqfHliYYPzZZk>		MVe0JIRigXN?	NFn6UJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZiM{mzUmwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iNEWuOkDPxE1w	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
LIXF 575L	Ml:2R5l1d3SxeHnjbZR6KGG\|c3H5		NUiyTFBPPCCmYYnz	M4DlZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxKYEZiNUe1UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB2Nz6yJO69VS5?	NIfJVGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
NCI-H23	M2\jbWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MljDOFYhcHK\|	Mmj3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh{MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNE[gbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IES5MlMh\|ryPLh?=	NWG3dHN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxN\|gxOjdpPkK5NVM5ODJ5PD;hQi=>
polycythemia vera hematopoietic progenitor cell	M3K4c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIXnXm42KHWP		M2HDWWdzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaIXtZY4heG:ueXP5eIhmdWmjII\ldoEhcGWvYYTvdI9q\XSrYzDwdo9o\W6rdH;yJINmdGy\|IHH0JFUhfU1iYomg[ZJ6fGi{b3nkJIJ2enO2LX\vdo1qdmdidX7peEBie3OjeTygUnVNVCB;IF7VUGwh\|ryPLh?=	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
A431	NHfrfnlHfW6ldHnvckBie3OjeR?=		NX:0[ox3OSCqcoO=	M1\wcWlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR\|MTDj[YxteyCycnX0doVifGWmIH\vdkAyKGi{czDmc4xtd3enZDDifUBGT0Zvc4TpcZVt[XSrb36gZpkhcW2vdX7vZoxwfCCjbnHsfZNqeyxiTmXMUEA:KE6XTFyg{txONg>?	NWXXe2pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
PC9	NITNPYVEgXSxdH;4bYNqfHliYYPzZZk>	MlL5NE4xODFidH:gNVAhfU1?	M{DZZlk3KGi{cx?=	MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|kh[2WubIOg[ZhxemW\|c3nu[{A4PDZvN{WwJJNmeXWnbnPlJIRmdGW2ZXSgSWdHWiCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjdDCwMlAxOSC2bzCxNEB2VSCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIF7VUGwhRSCQVVzMJO69VS5?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
NCI-H1975	M3nVXmN6fG:2b4jpZ4l1gSCjc4PhfS=>	MnXtNE4xODFidH:gNVAhfU1?	MnfIPVYhcHK\|	M2\0SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiVEe5NG0h[W6mIFy4OVhTKG23dHHueEBifCByLkCwNUB1dyBzMDD1UUBi\nSncjC5OkBpenNiYomgZ4VtdCC2aYTldk1odG9iYYPzZZktKE6XTFygQUBPXUyOIN88UU4>	NXnRXZhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
Huh7.5	NWPhTI4xSW62aY\pdoFtKGG\|c3H5		MWKzNEBucW6\|	NFqwT2NCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSyC4aYL1d{BLPi:MRligbY5n\WO2ZXSgbY4hcHWvYX6gTJVpPy53IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUEOYIILldIxq[2G2aX;uJJBz\XS{ZXH0[YQh\m:{IEOwJI1qdnNiZn;scI94\WRiYomgbY5n\WO2aX;uJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBlgWViYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCDY4Tpeol1gSB;IF7VUGwh\|ryPLh?=	Mn3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkWyNFgoRjJ4OUK1NlA5RC:jPh?=
A673	M1XQWZFJXFNiYYPzZZk>			MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	NXjkcXJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NELNPHZyUFSVIHHzd4F6			NYTVSXZweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MliwdWhVWyCjc4PhfS=>			NYTFZlVGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	M3zvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MXLxTHRUKGG\|c3H5			NVSxW3BJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NEfIXldyUFSVIHHzd4F6			NVPMSI1xeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	Ml[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NXXlcohueUiWUzDhd5NigQ>?			NXK0RmdoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	NIfJSZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NIXCfVByUFSVIHHzd4F6			M1r0d5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|LDDOWWxNKD1iTmXMUEDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NGKxO4VyUFSVIHHzd4F6			MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	M13CRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	M1vsTZFJXFNiYYPzZZk>			NH;BVIZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	M{PLRpFJXFNiYYPzZZk>			NV7FUYxSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NFvK[lJyUFSVIHHzd4F6			MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	M2\TdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NEnDVVZyUFSVIHHzd4F6			NXvTOVBEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJMtKE6XTFygQUBPXUyOIN88UU4>	M17zPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NGTXSGxyUFSVIHHzd4F6			MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NGHvOYZyUFSVIHHzd4F6			NUPX[Y1leUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	NGrjR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MUPxTHRUKGG\|c3H5			MoXudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHNuIF7VUGwhRSCQVVzMJO69VS5?	M1rr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NGPpUGZyUFSVIHHzd4F6			MnHtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	NFTzfWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MVnxTHRUKGG\|c3H5			NYDhTlJ4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	MnnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HCC827	M3nxZ2Fxd3C2b4Ppd{Bie3OjeR?=	M4fhUFEhfU1?	NF7hWnEzPCCqcoO=	MoLTTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB{NDDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDifUBndG:5IHP5eI9u\XS{eTygUnVNVCB;IF7VUGwh\|ryPLh?=	Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
NCI-H1648	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NUTzZoxRUUN3MDC9JFAvODRyMEKg{txO	M1rp[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-12	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnzuTWM2OCB;IECuNFU1PDFizszN	NF;acGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
ECC12	M{Dy[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NXrSUVFqUUN3MDC9JFAvODhyNUKg{txO	NX[3THhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
BB30-HNC	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1;SUGlEPTBiPTCwMlE1PzZ3IN88US=>	NGrkTZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LB996-RCC	NIWzVoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NHnjU\|NKSzVyIE2gNE41ODF4MTFOwG0>	NFTUeVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
EW-24	NHr2U5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NW[4VVBPUUN3MDC9JFAvPTl2NEOg{txO	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LC-1F	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NELWfVNKSzVyIE2gNE43ODZ\|MjFOwG0>	MmHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TK10	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MUfJR\|UxKD1iMD64OVg4QCEQvF2=	NF;ONG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A388	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NVuxXnJPUUN3MDC9JFEvODl\|ODFOwG0>	NHfPc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
EKVX	NIfVNIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoHPTWM2OCB;IEGuNVI{PTRizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-9	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1r6fWlEPTBiPTCxMlIzPTFzIN88US=>	NWHtfY5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-1	Mm\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mo\jTWM2OCB;IEGuOFA1QCEQvF2=	NUTCN\|BpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MOLT-16	Mon3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYrJR\|UxKD1iMT65NlkzPSEQvF2=	M{fYTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-6	NHfhZotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{PQfmlEPTBiPTCyMlU3PzhizszN	NHP2e5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
697	NGHJZYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M3v6OmlEPTBiPTCyMlY2OzB3IN88US=>	NV;rOZpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
A253	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NY\oPVR4UUN3MDC9JFIvPzVzNjFOwG0>	NI\rPWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OS-RC-2	NEP2WHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MmGwTWM2OCB;IEKuPVQxOjNizszN	M3i4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KS-1	MmTIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MmW2TWM2OCB;IEKuPVQ2PDJizszN	M17PRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MC116	MnnFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NWLpNmJKUUN3MDC9JFMvPjJyNEmg{txO	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB2241-RCC	NVfETHdIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MX3JR\|UxKD1iMz64NVczQSEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
RL95-2	M2rrUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NFH6d2hKSzVyIE2gOE4xOzN{IN88US=>	MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HCE-T	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{PLWWlEPTBiPTC0MlExOTh6IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCCIT	M1yyNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUjJR\|UxKD1iND6zPFQ6PyEQvF2=	NUnyZWhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
GCIY	NFL2N\|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{DVR2lEPTBiPTC0MlY{PTN{IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB1047-RCC	M4XYbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M16zSGlEPTBiPTC0Mlk5Ozd7IN88US=>	M3[ydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A3-KAW	MoPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NEHyRXFKSzVyIE2gOU41Ozl2NjFOwG0>	MmLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-15	NFHCPGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MULJR\|UxKD1iNT60O\|I4KM7:TR?=	M{fzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NOS-1	M1y2Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M{LBNmlEPTBiPTC1MlQ6Ozh4IN88US=>	NE\DdGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
EW-16	NXHBcIo5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NIfo[YZKSzVyIE2gOk4zPTN6NzFOwG0>	MlvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LAMA-84	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MX\JR\|UxKD1iNz6wNFc4OiEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-5	NEHaeJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXrJR\|UxKD1iNz6wOFI1PyEQvF2=	MoPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HEL	NX;JTGE3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NIXQW2lKSzVyIE2gO{4{OzV4NDFOwG0>	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H209	Ml3ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MnnQTWM2OCB;IEiuNFQ1OTJizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
DJM-1	NHHZcnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MkjoTWM2OCB;IEiuOVI6PjRizszN	M{DNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
OVCAR-4	NV73THlwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnP0TWM2OCB;IEiuPFQzOTlizszN	M{nqc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB17	NWLaS4pET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NV;1e4xvUUN3MDC9JFkvOjV7OUGg{txO	NX;rWpY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NVizSFRoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NGPPXnNKSzVyIE2gPU4{PTd5NjFOwG0>	NGXOT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB5	NGPrbWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{Cwd2lEPTBiPTCxNE4zQSEQvF2=	MlPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BV-173	NHL6VoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYXJR\|UxKD1iMUCuN\|I4OiEQvF2=	NYrP[lY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MPP-89	NH;l[GNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVjJR\|UxKD1iMUCuOFQzKM7:TR?=	Ml;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
RPMI-6666	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1OxdWlEPTBiPTCxNE41QTZ7IN88US=>	NIDjfoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MS-1	NH7ifmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NVzib2tlUUN3MDC9JFEyNjR4NUig{txO	NYfpOohKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ALL-PO	Mn7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NYDNPGU4UUN3MDC9JFEyNjVzN{mg{txO	M3Poe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB10	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NG\oeJhKSzVyIE2gNVEvPzV6NzFOwG0>	M4T2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB13	M1nKR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M33PXWlEPTBiPTCxNU46QTF2IN88US=>	NEDxdXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SCH	NFK5WHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MnvmTWM2OCB;IEGyMlE5QTFizszN	NWPGd4VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ES6	M{jTWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NWPuOoJzUUN3MDC9JFEzNjR5NTFOwG0>	NFXF[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
ETK-1	NHXL[29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NYfaN29tUUN3MDC9JFE1NjB6OEWg{txO	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
ES4	NWDENVcxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NULpcINNUUN3MDC9JFE1Njh2NEWg{txO	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
K-562	NF\3SYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NYK4dZJvUUN3MDC9JFE2NjhzNDFOwG0>	NV7Tc2xNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
D-502MG	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NFTNcY5KSzVyIE2gNVcvOzR4ODFOwG0>	MlPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB647-SCLC	NWPr[\|k4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3fUZWlEPTBiPTCxO{44PzJ4IN88US=>	NF7xU5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-10	M{DJVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MmXHTWM2OCB;IEG4MlEyOzhizszN	NHvMbVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MZ1-PC	NF;FdWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			Ml7lTWM2OCB;IEG4MlM4PzRizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CTB-1	NWDWXZhsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NHH2codKSzVyIE2gNVgvPTB5NTFOwG0>	NHLiUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NMC-G1	NX\NeFA6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnnFTWM2OCB;IEG4MlgxOjlizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
C2BBe1	NYrr[3MzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NF3OfFdKSzVyIE2gNVgvQDZ4NDFOwG0>	NGfWSoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M3;mZWlEPTBiPTCxPU42PDh{IN88US=>	NGjvNVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HCC2157	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M174bWlEPTBiPTCyNE4{OzZzIN88US=>	NV\HNHE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
Becker	MnjaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NWTROHYzUUN3MDC9JFIxNjN3NEGg{txO	MoK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ST486	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MkLhTWM2OCB;IEKwMlQxQTNizszN	Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LC-2-ad	MoKzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NImwVotKSzVyIE2gNlAvQTZ\|NzFOwG0>	M1fuTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H747	Mlm1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M1;UOWlEPTBiPTCyNU42OTN7IN88US=>	Mn;CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BE-13	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{eyRmlEPTBiPTCyNU45OTV6IN88US=>	Mn7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
no-11	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NYLxOJlCUUN3MDC9JFIyNjlzME[g{txO	NH3Cdos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-8	MonFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlK0TWM2OCB;IEKyMlY{OThizszN	M4HTN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB6	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NY\jUpNJUUN3MDC9JFIzNjh\|MEOg{txO	NVe1NnM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
BB65-RCC	NFHNO3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NH;qfZpKSzVyIE2gNlIvQTZ{MzFOwG0>	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SK-UT-1	NXnGNGdiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NF6wT4ZKSzVyIE2gNlMvOTR7NzFOwG0>	M{ftOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-392MG	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnHKTWM2OCB;IEK0MlI6OzRizszN	NFfnOHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
JVM-2	NWPlOmZjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MXLJR\|UxKD1iMkSuOVM{OyEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
SW954	MlPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M{\nfWlEPTBiPTCyOE42QTF4IN88US=>	M4HydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
QIMR-WIL	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnuwTWM2OCB;IEK1MlE6PzNizszN	MonWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MEG-01	NX\ZeZlmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M1j4[GlEPTBiPTCyOU46ODF4IN88US=>	NIDzNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A101D	NH7BNYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NV\aWmZIUUN3MDC9JFI5NjdzM{mg{txO	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB831-BLC	Mm\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Ml3UTWM2OCB;IEOwMlQxODRizszN	NV7CPYRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KGN	NXXLepZpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			Ml\UTWM2OCB;IEOwMlg3PjFizszN	NH\wfmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HC-1	MnrrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NWmyWYRbUUN3MDC9JFMyNjN3MEig{txO	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
CP66-MEL	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{PyWWlEPTBiPTCzNU45OzZ4IN88US=>	M{i0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-542MG	NGjUSJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M3zl[GlEPTBiPTCzNk41OzN5IN88US=>	NXrPOYtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LS-513	NUPLTokyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MoSwTWM2OCB;IEOzMlQ5PDRizszN	NG\OOW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
DOHH-2	NGXEb2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NVfqWlFuUUN3MDC9JFM{NjZ3OEmg{txO	NYPaUllCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NB69	NETt[m1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			Mo[yTWM2OCB;IEOzMlkzODZizszN	NEfRTI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SW962	NF3mWGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXTJR\|UxKD1iM{WuO\|IyPyEQvF2=	M3nTOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
J-RT3-T3-5	NYHneJA3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MX7JR\|UxKD1iM{[uNFczPCEQvF2=	NWDCbolTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6	NIXFXYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXfJR\|UxKD1iM{[uOVM2QSEQvF2=	M3\HXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MLMA	Ml3KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M2nqTWlEPTBiPTCzPE43PTJizszN	NXPOVFZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HOP-62	M3;JXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MXPJR\|UxKD1iM{muNVc3PSEQvF2=	NX;iOHNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LP-1	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MYLJR\|UxKD1iM{muOFQyPSEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
ONS-76	M{[3Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUfJR\|UxKD1iM{muPVE2OiEQvF2=	M3TRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KNS-42	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MX\JR\|UxKD1iNECuNFU{OSEQvF2=	M2\nXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H1581	NYHBfoV6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnGxTWM2OCB;IESxMlE5PDJizszN	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
DSH1	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Mn;ZTWM2OCB;IESyMlQxPyEQvF2=	NUfZWIg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M13kOmlEPTBiPTC0Nk45OzlizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-247MG	NEPxbWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NFf1WYJKSzVyIE2gOFUvPzF7IN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MC-CAR	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1KxPGlEPTBiPTC0OU46PjlzIN88US=>	M3SwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EW-1	M4nyNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYXJR\|UxKD1iNEeuOVYzPCEQvF2=	NHzzdmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
GI-ME-N	MofpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MV3JR\|UxKD1iNEiuNVM5PCEQvF2=	NFvkS3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BT-474	M1;HO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NFjiZ3NKSzVyIE2gOFgvOTd\|ODFOwG0>	NYnw[VZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	M3[0WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NELNXppKSzVyIE2gOFgvPzV4MzFOwG0>	MnHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Met / Met / p-Axl / Axl / pERK / ERK / pEGFR / EGFR / p-STAT3 / STAT3 / p-Akt / Akt; PubMed: 28604685 Nat Neurosci (b) Patient derived primary GBM neurospheres (GBM9) were exposure to erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (c–d) A similar experiment in patient derived GBM neurospheres from two different patients (GBM39 and SK987). (e) U87EGFR cells were treated with erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (f) Similar experiment was conducted in U87EGFRvIII cells. p-Raf-1 / Raf-1 / p-MEK / MEK; PubMed: 27508092 Am J Cancer Res Cells from both ER and ECR groups were treated with 3 μM erlotinib for 72 h. Cell lysates were used for Western blotting with indicated antibodies. cleaved PARP / PARP; PubMed: 27508092 Am J Cancer Res HCC827 or H1650 cells were treated with DMSO, celecoxib, erlotinib alone, or in combination for 48 h. Western blot analysis showed that cleaved PARP was higher in cells after combination treatment. p27 / pS10-p27 / pT157-p27 / pT187-p27; PubMed: 21045138 Mol Cancer Ther BT-474 and SK-BR-3 cells were treated with erlotinib at 0, 1, or 3 µM for 72 h, after which expression of total p27, p27 phosphorylated at S10 (pS10-p27), pT157-p27, and pT187-p27 was assessed by western blot analysis. β-actin was used as a loading control. Bcl-2 / Bcl-xl / Mcl-1 / Bax / Bak / Bad / Bim EL / PUMA; PubMed: 17927446 PLoS Med Effects of erlotinib treatment on proapoptotic and antiapoptotic proteins in H3255 cells. H3255 cells were treated with different concentrations of erlotinib for 24 h. Cell lysates were examined by immunoblotting using antibodies specific for the indicated proteins.	28604685 27508092 21045138 17927446
Immunofluorescence	Bax / Cyto C; PubMed: 17927446 PLoS Med Erlotinib induces colocalization of BAX and cytochrome c in PC-9 cells undergoing apoptosis. Cells were grown in Lab-Tek II chambers and treated with 100 nM erlotinib or DMSO for 48 h, fixed and immunostained with antibodies against BAX (green) and cytochrome c (red) or with DAPI to detect DNA (blue). Cells were imaged by confocal microscopy. E-cadherin / β-catenin / Vimentin; PubMed: 19825949 Clin Cancer Res SUM149 cells were plated in 3D culture without or with erlotinib for 4 days. Immunofluorescence analysis was performed to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with DAPI. EGFR ; PubMed: 27612423 Oncotarget HCC827 (delE746-A750), NCI-H3255 (L858R) and NCI-H1975 (L858R/T790M) cells were treated either with DMSO (control) or with 3 μM erlotinib/200 nM AZD9291 for the indicated time points. Cells were fixed and stained with EGFR antibody (red) and DAPI (blue, DNA dye) as described in the Materials and Methods. Representative images showing decreased EGFR immunofluorescence in erlotinib-sensitive HCC827 and NCI-H3255 cells. AZD9291 also reduced EGFR immunofluorescence even in NCI-H1975 cells. Scale bars, 10 μm.	17927446 19825949 27612423
Growth inhibition assay	Cell viability; PubMed: 30377412 Cancer Cell Int a The MTT assay for PANC-1 viability. Different doses of erlotinib were added to the medium of PANC-1 cells. b LDH release was used to evaluate the cell death in PANC-1 cells in the presence of erlotinib. c The MTT assay for PaCa-2 cells in the presence of erlotinib treatment. d LDH release was used to evaluate the cell death in PaCa-2 cells in the presence of erlotinib.	30377412

体内研究

Erlotinib单独作用于H460a肿瘤模型，抑制肿瘤生长，这种作用存在剂量依赖性，与药物的循环水平相关。

激酶实验：^[1]	- 合并激酶实验: 每孔使用100 μL 溶于PBS的0.25 mg/mL PGT对96孔板包被，然后在37^oC温育过夜。吸取移除过量PGT，使用冲洗 buffer (0.1% Tween-20，溶于PBS)清洗实验板3次。在 50 μL 50 mM HEPES (pH 7.3), 含125 mM NaCl, 24 mM MgCl₂, 0.1 mM 原钒酸钠, 20 μM ATP, 1.6 μg/mL EGF, 以及从A431细胞膜上亲和纯化的15 ng EGFR的混合物中进行激酶反应。加入溶于 DMSO的 Erlotinib，DMSO 终浓度为2.5%。加入ATP，开始磷酸化，在室温下进行8分钟，且持续震荡。加入吸取的反应混合物，激酶反应终止，使用冲洗 buffer冲洗4次。磷酸化的PGT与50 μL每孔 HRP联合的PY54 抗磷酸抗体[在封闭液(3% BSA 和0.05% Tween-20，溶于 PBS)中稀释到0.2 μg/mL]温育25分钟后，测量磷酸化的PGT。吸取移除抗体，使用冲洗buffer冲洗实验板4次。加入 TMB 微孔过氧化物酶底物，每孔50μL，进行比色分析，然后加入0.09 M 硫酸，每孔50 μL，终止反应。在450 nm处测定吸光值而测定磷酸化。
细胞实验：^[3]	- 合并 Cell lines: HPAC细胞系和Capan-1细胞 Concentrations: 0.01 μM-10 μM Incubation Time: 4天或6天 Method: 为了测评对细胞增殖的抑制作用，进行MTT实验。细胞在96孔板上在37^oC下预温育，单独加入Erlotinib 和Gemcitabine，或者联合加入。在37^oC下处理4天(HPAC细胞)或6天(Capan-1 细胞)后，每孔加入10 mL MTT，然后在37^oC下温育2-5小时。使用Benchmark Plus 酶标仪在450和600 nm处测定每孔的光密度。每组每种药物实验独立重复进行2次或3次。按如下计算细胞增殖抑制百分数: [(药物处理孔中的平均吸光值-无细胞孔中平均吸光值)/(对照组孔中平均吸光值-无细胞孔中平均吸光值)] × 100。 (Only for Reference)
动物实验：^[6]	- 合并 Animal Models: 携带HPAC细胞的雄性5周大的BALB-nu/nu小鼠 Dosages: 50 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	4 mg/mL warmed (9.3 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 15% Captisol	16 mg/mL warmed (suspension)

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Erlotinib HCl (OSI-744) SDF

分子量	429.90
化学式	C₂₂H₂₃N₃O₄.HCl
CAS号	183319-69-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	CP358774, NSC 718781

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

研究领域

产品类型

定制您的化合物库